SUMMARY
Meredith R. Wicklund, M.D., is a behavioral neurologist with a clinical practice and research interest in Alzheimer's disease and related disorders. To aid in early detection, Dr. Wicklund seeks to understand the clinical, neuropsychological, and imaging features of dementias and neurodegenerative diseases. She and her colleagues also study investigational drugs and other therapeutics for these diseases.
Dr. Wicklund is Mayo Clinic's site director for the Arizona Alzheimer's Consortium, which involves participation in several research studies focusing on understanding the neurobiology of Alzheimer's disease. Other aspects of these studies look at early detection, treatment and prevention of Alzheimer's disease and related disorders.
Focus areas
- Alzheimer's disease. Dr. Wicklund studies the clinical, neuropsychological, neuroimaging and fluid biomarker characteristics of typical and atypical Alzheimer's disease.
- Neurodegenerative dementias. Dr. Wicklund examines the clinical, neuropsychological, neuroimaging and fluid biomarker characteristics of neurodegenerative dementias as well. These conditions include frontotemporal dementia, primary progressive aphasia, corticobasal syndrome and Lewy body dementia.
- Investigational therapeutics. Dr. Wicklund leads clinical trials for investigational drugs and other therapeutics for the treatment and prevention of Alzheimer's disease.
Significance to patient care
Alzheimer's disease and related disorders are devastating conditions that can be difficult to detect and diagnose in their early stages, when therapeutics and other interventions are more likely to be beneficial. Dr. Wicklund's research aims to improve the early detection and diagnostic accuracy of these disorders. She also seeks to advance scientific knowledge for optimal therapeutics and interventions to improve patient quality of life and potentially even reverse or halt the progression of these disorders.